



Improving Outcomes in Relapsed/Refractory Paediatric and Young Adult ALL Patients with CAR-T Therapy

SIOPe 2022 Novartis-sponsored pre-recorded ESH encore Virtual Satellite

Symposium agenda

Meeting objectives

- Discuss practical considerations within the clinic when identifying and preparing relapsed/refractory paediatric and young adult ALL patients for CAR-T therapy
- Examine real-world experience with CAR-T therapy, including registry data
- Explore the future directions with cell and gene technologies for CAR-T in relapsed/refractory paediatric and young adult ALL patients

Meeting: Novartis-sponsored Virtual Satellite Symposium at SIOPe 2022

Date: 23 March 2022

Time: 12:15–13:00 (CET)

Location: VIRTUAL

Time	Topic	Speaker
12:15	Welcome and Introduction	Chair: G. Kriván (Hungary)
12:20	Within the Clinic: Practical Considerations for Treatment with CAR-T Therapy	S. Ghorashian (UK)
12:40	Looking Forward: Real-World Experience with CAR-T Therapy and Future Directions with Cell and Gene Technologies	E. Jacoby (Israel)
13:00	Meeting Close	

ALL, acute lymphoblastic leukaemia; CAR-T, chimeric antigen receptor T-cell; SIOPe, The European Society for Paediatric Oncology

Page 2 of 2

This symposium is organised and funded by Novartis.

